The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Whether or not the benefits of antithymocyte globulin (ATG) on engraftment and GVHD are offset by increased risk of relapse, delayed T-cell recovery and increased infections remains controversial. We retrospectively studied the effect of ATG in 144 AML patients, 34 of whom received ATG, undergoing reduced intensity conditioning (RIC) umbilical cord blood transplantation (UCB) or HLA-matched sibling PBSC. ATG patients had not received intensive chemotherapy for 3 months before transplantation for UCB, 6 months for PBSC. There were no differences in engraftment between ATG and non-ATG patients. The cumulative incidences of TRM as well as acute and chronic GVHD in ATG-treated patients were not statistically different. ATG patients had significantly more infections between 46 and 180 days post transplantation. Unexpectedly, after adjusting for donor type, relapse was lower among ATG recipients (relative risk (RR) 0.5, 95% confidence interval (CI) 0.3-1.0, P=0.04). In summary, administration of ATG to AML patients undergoing RIC had no adverse impact on major clinical outcomes. ATG may be indicated for patients at higher risk of graft failure after allogeneic hematopoietic cell transplantation (allo-HCT).

Original languageEnglish (US)
Pages (from-to)1498-1504
Number of pages7
JournalBone marrow transplantation
Volume49
Issue number12
DOIs
StatePublished - Dec 11 2014

Fingerprint Dive into the research topics of 'The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML'. Together they form a unique fingerprint.

Cite this